Sugi Predict

Sugi Predict / Compounds / SCHEMBL16650516

SCHEMBL16650516

SCHEMBL16650516

Cn1cc(B2OC(C)(C)C(C)(C)O2)cc(F)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 9/20 0.40
▸ LIPG Q9Y5X9 9/20 0.40
▸ ROCK1 Q13464 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ TDO2 P48775 1/20 0.38
▸ CA1 P00915 3/20 0.36
▸ CA2 P00918 3/20 0.36
▸ CA9 Q16790 3/20 0.36
▸ JAK2 O60674 2/20 0.34
▸ BTK Q06187 2/20 0.34
▸ F11 P03951 2/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ F2 P00734 1/20 0.33
▸ PRSS1 P07477 1/20 0.33
▸ PRSS2 P07478 1/20 0.33
▸ PRSS3 P35030 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA3 P07451 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA6 P23280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31752740 0.89 LPL (0.37) LPLLIPGROCK1IDO1TDO2
SCHEMBL23001755 0.84 CA1 (0.36) LPLLIPGROCK1IDO1TDO2
SCHEMBL14719271 0.82 BRD4 (0.40) LPLLIPGIDO1TDO2CA1
SCHEMBL21224665 0.81 AURKA (0.40) LPLLIPGIDO1TDO2CA1
SCHEMBL16651646 0.81 CA1 (0.36) LPLLIPGIDO1TDO2CA1
SCHEMBL16650813 0.80 F11 (0.36) LPLLIPGIDO1TDO2CA1
SCHEMBL28645604 0.80 LPL (0.37) LPLLIPGROCK1IDO1TDO2
SCHEMBL18496375 0.79 LIPG (0.38) LPLLIPGROCK1IDO1TDO2
SCHEMBL29848701 0.78 BRD4 (0.34) LPLLIPGIDO1TDO2CA1
SCHEMBL13092721 0.78 CA1 (0.34) LPLLIPGIDO1TDO2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-23 — — US disclosed
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 — — US disclosed
WO-2025264700-A1 GIP RECEPTOR AGONIST COMPOUNDS ELI LILLY AND COMPANY (US) 2025-12-26 — — WO disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF SLC10A1, NR3C2, CYP2C8 LPL 1376/4885LIPG 119/4885ROCK1 2710/4885
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LPL 2973/4885LIPG 2990/4885ROCK1 1445/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LPL 2973/4885LIPG 2990/4885ROCK1 1445/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LPL 2973/4885LIPG 2990/4885ROCK1 1445/4885
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 LPL 908/4885LIPG 2986/4885ROCK1 3754/4885
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GCGR LPL 642/4885LIPG 2425/4885ROCK1 4467/4885
US-20150183784-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LPL 2973/4885LIPG 2990/4885ROCK1 1445/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 LPL 2973/4885LIPG 2990/4885ROCK1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.